CVRx (NASDAQ:CVRX) Rating Lowered to “Sell” at Wall Street Zen

Posted by Geri Gentry on Nov 9th, 2026

CVRx (NASDAQ:CVRX – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the company. Piper Sandler cut CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a report on Friday, August 7th. Craig Hallum lowered CVRx from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research note on Friday, August 7th. Canaccord Genuity Group cut CVRx from a “buy” rating to a “hold” rating and decreased their target price for the company from $5.00 to $2.00 in a research report on Friday. William Blair cut CVRx from an “outperform” rating to a “market perform” rating in a research report on Friday. Finally, Lake Street Capital downgraded CVRx from a “buy” rating to a “hold” rating and lowered their target price for the stock from $14.00 to $3.50 in a research note on Friday, August 7th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $3.70.

Check Out Our Latest Report on CVRx

CVRx Price Performance

Shares of CVRX opened at $0.87 on Friday. CVRx has a one year low of $0.77 and a one year high of $10.28. The company has a market cap of $23.14 million, a P/E ratio of -0.43 and a beta of 0.81. The company has a debt-to-equity ratio of 4.24, a current ratio of 6.80 and a quick ratio of 5.71. The firm has a 50 day simple moving average of $2.08 and a two-hundred day simple moving average of $5.16.

CVRx (NASDAQ:CVRX – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The business had revenue of $13.83 million during the quarter, compared to analyst estimates of $13.93 million. CVRx had a negative net margin of 88.28% and a negative return on equity of 208.45%. Research analysts forecast that CVRx will post -2.00 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Brent Binkowski bought 26,223 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were purchased at an average price of $2.91 per share, for a total transaction of $76,308.93. Following the completion of the transaction, the chief operating officer directly owned 56,514 shares of the company’s stock, valued at approximately $164,455.74. This represents a 86.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 16.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CVRX. Deutsche Bank AG bought a new position in shares of CVRx in the 2nd quarter valued at $62,000. Renaissance Technologies LLC acquired a new stake in shares of CVRx during the 1st quarter valued at $183,000. Bank of America Corp DE acquired a new stake in shares of CVRx during the 2nd quarter valued at $102,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of CVRx during the 2nd quarter valued at $107,000. Finally, Bank of New York Mellon Corp grew its position in CVRx by 7.4% during the 1st quarter. Bank of New York Mellon Corp now owns 38,542 shares of the company’s stock worth $365,000 after acquiring an additional 2,649 shares during the last quarter. 75.27% of the stock is currently owned by institutional investors and hedge funds.

CVRx News Roundup

Here are the key news stories impacting CVRx this week:

Neutral Sentiment: Trading in CVRx was temporarily paused under a Limit Up-Limit Down (LULD) volatility mechanism. The halt signals unusually volatile trading but does not, by itself, explain the move. Trading halt notice
Negative Sentiment: CVRx reported Q3 revenue of $13.83 million, below the roughly $13.93 million analyst expectation, and a loss of $0.52 per share versus estimates of about $0.50. Revenue declined year over year, and the company lowered its FY2026 outlook, raising concerns about growth and execution. CVRx reports Q3 revenue decline and lowers outlook
Negative Sentiment: Canaccord Genuity cut its rating from Buy to Hold and reduced its price target from $5 to $2. William Blair also downgraded the stock, moving from Outperform to Market Perform. The lowered ratings and targets add pressure despite the $2 target remaining above the recent share price. William Blair downgrade

About CVRx

(Get Free Report)

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.